Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808899 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL808800 | 0.87 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL808809 | 0.84 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL27633084 | 0.84 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL808788 | 0.84 | METAP2 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL809130 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL808962 | 0.82 | KMT2A (0.38) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 | |
| SCHEMBL808922 | 0.82 | ACP3 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL4341912 | 0.82 | ACP3 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL9491318 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958940-B1 | CONDENSATION REACTION BY METAL CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110098479-A1 | CONDENSATION REACTION BY METAL CATALYST | MASHIMA KAZUSHI | 2011-04-28 | — | — | US | disclosed |
| US-7888513-B2 | Condensation reaction by metal catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | OSAKA UNIVERSITY (JP) | 2009-08-06 | — | — | US | disclosed |
| CN-100436406-C | Process for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL CO (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1958940-A1 | CONDENSATION REACTION BY METAL CATALYST | Takasago International Corporation (JP) | 2008-08-20 | — | — | EP | disclosed |
| CN-101125833-A | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| CN-1898193-A | Method for producing optically active bisamidealcohol compound | SUMITOMO CHEMICAL CO (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098479-A1 | CONDENSATION REACTION BY METAL CATALYST | C9, CBR3, C1R | ALDH1A1 2265/4885CYP1A2 379/4885CYP2C9 672/4885 |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | ALDH1A1 1303/4885CYP1A2 791/4885CYP2C9 1613/4885 |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | C9, CBR3, C1R | ALDH1A1 2265/4885CYP1A2 379/4885CYP2C9 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.